Private Capital Advisors Inc. Invests $259,000 in Immunome, Inc. (NASDAQ:IMNM)

Private Capital Advisors Inc. bought a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 38,501 shares of the company's stock, valued at approximately $259,000.

A number of other institutional investors and hedge funds have also modified their holdings of IMNM. BNP Paribas Financial Markets acquired a new position in shares of Immunome in the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS bought a new position in Immunome during the fourth quarter worth about $75,000. AlphaQuest LLC lifted its position in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after acquiring an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome during the 4th quarter valued at approximately $95,000. 44.58% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Jean Jacques Bienaime purchased 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were bought at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the acquisition, the director owned 36,415 shares of the company's stock, valued at approximately $341,572.70. This represents a 15.92% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.60% of the stock is owned by company insiders.

Immunome Trading Up 7.7%

NASDAQ:IMNM traded up $0.75 during mid-day trading on Thursday, reaching $10.42. The company's stock had a trading volume of 521,410 shares, compared to its average volume of 906,115. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.81. The stock has a market cap of $906.21 million, a P/E ratio of -3.24 and a beta of 1.92. The firm's fifty day moving average price is $8.72 and its two-hundred day moving average price is $8.89.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative return on equity of 71.65% and a negative net margin of 1,875.21%. The business had revenue of $2.93 million during the quarter, compared to the consensus estimate of $0.46 million. Analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IMNM has been the topic of several recent research reports. Stephens reiterated an "overweight" rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Wedbush restated an "outperform" rating and set a $21.00 price target (down previously from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. Lake Street Capital started coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price target on the stock. Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Guggenheim lowered their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $23.33.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.